Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma

NCT00499616 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00499616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00499616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
October 8, 2007
Completion date
June 30, 2021
Enrollment
464 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma